Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Pfizer Announces New Long-Term Relapse Prevention Data For PRISTIQ 50 Mg/day

Pfizer Inc. (PFE: Quote) announced new data on PRISTIQ (desvenlafaxine) Extended Release Tablets 50 mg/day for the treatment of major depressive disorder, or MDD, in adults, including a long-term relapse prevention study.

According to the company, these new data, and data from a study in peri- and post-menopausal women with MDD, add to the existing efficacy and safety profile of PRISTIQ for the treatment of MDD. Lastly, new data also provide information regarding the discontinuation of PRISTIQ 50 mg/day for the treatment of adults with MDD.

These new PRISTIQ 50 mg/day data focus on key factors - efficacy, safety, long-term use and discontinuation - that clinicians often consider when assessing antidepressants for the treatment of MDD.

Click here to receive FREE breaking news email alerts for Pfizer Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The Eurozone private sector growth eased more-than-expected in August as weak manufacturing performance hurt Germany's expansion, while the French private sector activity stagnated. The Eurozone composite output index fell to 52.8 in August from 53.8 in July, flash data from Markit Economics showed Thursday. The indicator was expected to fall marginally to 53.4. In the worst blow Israel inflicted on Hamas since Operation Protective Edge began on July 8, three senior Hamas military commanders were killed in overnight air strikes on Gaza. The Islamist movement that controls the Gaza Strip said Mohammed Abu Shammala, Raed al-Attar and Mohammed Barhoum were killed in a bombing of a house in the southern town of Rafah. They were the Hamas masterminds of smuggl Computer and printer maker Hewlett-Packard Co. (HPQ) said Wednesday after the markets closed that its third quarter profit fell 29% from last year, hurt mainly by higher restructuring charges even as revenue grew 1%. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations, but its quarterly revenue beat analysts' forecast.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.